dc.contributor.author | Aliyeva, Ayten | |
dc.contributor.author | KASAPÇOPUR, Özgür | |
dc.contributor.author | Koker, Oya | |
dc.contributor.author | Sahin, Sezgin | |
dc.contributor.author | BARUT, Kenan | |
dc.contributor.author | ADROVIC YILDIZ, Amra | |
dc.contributor.author | Yildiz, Mehmet | |
dc.contributor.author | HAŞLAK, Fatih | |
dc.date.accessioned | 2021-03-05T14:46:30Z | |
dc.date.available | 2021-03-05T14:46:30Z | |
dc.identifier.citation | ADROVIC YILDIZ A., Yildiz M., HAŞLAK F., Koker O., Aliyeva A., Sahin S., BARUT K., KASAPÇOPUR Ö., "Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study", RHEUMATOLOGY INTERNATIONAL, 2020 | |
dc.identifier.issn | 0172-8172 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_b8c5d13a-ee18-4726-bea0-1d2e2672a990 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/122933 | |
dc.identifier.uri | https://doi.org/10.1007/s00296-020-04732-z | |
dc.description.abstract | To evaluate the efficacy and safety of anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) as a treatment option of juvenile systemic sclerosis (JSS). Nine JSS patients were assigned to a TCZ, additionally to conventional treatment (steroids, methotrexate, mycophenolate-mofetil). The modified Rodnan skin score (mRSS), carbon-monoxide diffusion capacity (DLCO), thorax high-resolution tomography (HRCT), patient global assessment (PGA) and Juvenile Systemic Sclerosis Severity (J4S) score were used to explore the efficacy of treatment. Nine JSS patients were treated with TCZ with a median treatment duration of 10 (1-21) months. Nine patients (77.8%) had radiologically confirmed improvement on thorax HRCT, 7 (77.8%) had decreased PGA (mean pre-treatment PGA 3.7 vs. 2.3 post-treatment PGA 2), 6 (66.7%) had increased DLCO (mean pre-treatment DLCO 69.14% vs. post-treatment DLCO 79.50%) after the TCZ treatment. In all patients mRSS and the J4S decreased: 26.1 vs. 19.7 and 8.2 vs. 4.7, respectively. Changes in mRSS, DLCO, PGA and J4S were statistically significant: p = 0.012, 0.04, 0.026 and 0.007, respectively. All patients tolerated well TCZ treatment. JSS is a rare condition characterized with skin fibrosis and internal organ involvement. Tocilizumab represents a potential treatment option for patients unresponsive to conventional treatment. Long-term prospective studies with higher number of patients are needed to provide more relevant data. | |
dc.language.iso | eng | |
dc.subject | İmmünoloji ve Romatoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ROMATOLOJİ | |
dc.title | Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study | |
dc.type | Makale | |
dc.relation.journal | RHEUMATOLOGY INTERNATIONAL | |
dc.contributor.department | İstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
dc.contributor.firstauthorID | 2359356 | |